Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community.
about
Enhancing case ascertainment of Parkinson's disease using Medicare claims data in a population-based cohort: the Cardiovascular Health Study.Estimating the prevalence of Parkinson's disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data.The decision-making process leading to deep brain stimulation in men and women with parkinson's disease - an interview studyGene-environment interactions in sporadic Parkinson's disease.National surveys: a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on diseaseParkinson's disease in Arabs: a systematic review.Systematic review of the prevalence and incidence of Parkinson's disease in Asia.The prevalence and incidence of Parkinson's disease in China: a systematic review and meta-analysis.Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson's disease in the Nordic region.Prevalence of Parkinson's disease in Estonia.Drug and treatment costs in Parkinson's disease patients in Sweden.Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study.Variations of mitochondrial DNA polymerase γ in patients with Parkinson's disease.Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson's disease in residents in long-term care facilities. SAGE Study Group.Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.Does L-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease?Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition.Sense of coherence is a sensitive measure for changes in subjects with Parkinson's disease during 1 year.Factors of importance to the caregiver burden experienced by family caregivers of Parkinson's disease patients.Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson's disease--a rCBF scintigraphy study.Parkinson's Disease in Sub-Saharan Africa: A Review of Epidemiology, Genetics and Access to Care.
P2860
Q30719731-E42B91D9-0475-4B72-BD83-B107C37B93A3Q31036797-C28B6419-C85D-4BAE-B831-40BC95FD6F21Q35156587-26CABF1C-242F-4A66-B3BA-DFCCAB93CD6EQ36521952-010329FB-5935-4817-BEF9-FE79E3BC0B8CQ36992154-4E03D0CE-B928-4059-A381-2E246A764711Q37149360-787A5DD4-A62C-470C-9B24-E501CD35CDE7Q37583187-29A3BB31-4352-4A35-8E82-8B4293484F1EQ38140733-A5000992-36E3-41EB-9FCF-437BA1DFFA4CQ38530328-DED7EC66-70AF-4AFE-8073-B166809A279FQ39632889-92983753-BD5A-4491-9BFB-C1C95CEE3076Q39763335-8663C531-E970-4552-A9CF-5FAA64592418Q43182154-CE5EDECA-F826-484A-BB6D-BFF8AA816EDEQ43481102-48D3854B-52C2-47F1-898F-A7047B3C094BQ44769658-CFD1D317-A5FE-41B7-833C-95B68CABFED0Q46596326-FE115E76-34EA-4434-9078-3EBD16B6B7F2Q47398409-1693504B-3C8A-43A8-BD3C-794177160559Q48363897-E439C47E-42EA-450A-B4A9-DA3158EC6B2BQ48592977-3DBA8DC7-4E53-4F5B-93AF-F6D8D61B611EQ53395934-E809C6ED-3AA5-4CC9-BE22-AE10A4CCD5F3Q53459629-271C6EA5-0667-484C-8212-7C03B3542231Q55171334-16249C6C-B75C-4FC6-ABD4-293CB8D86B31
P2860
Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community.
@en
Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community.
@nl
type
label
Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community.
@en
Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community.
@nl
prefLabel
Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community.
@en
Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community.
@nl
P50
P1476
Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community.
@en
P304
P356
10.1016/0895-4356(96)00003-0
P4011
6fd9e9ce25b97dce8cc3929ca64613eb300d074d
P407
P577
1996-06-01T00:00:00Z